Bank of America’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-57,363
| Closed | -$72K | – | 8833 |
|
|
2022
Q1 | $72K | Sell |
57,363
-27
| -0% | -$29 | ﹤0.01% | 7019 |
|
|
2021
Q4 | $67K | Buy |
57,390
+27
| +0% | +$40 | ﹤0.01% | 7073 |
|
|
2021
Q3 | $110K | Buy |
57,363
+177
| +0.3% | +$348 | ﹤0.01% | 6672 |
|
|
2021
Q2 | $134K | Sell |
57,186
-14,601
| -20% | -$35.2K | ﹤0.01% | 6342 |
|
|
2021
Q1 | $195K | Sell |
71,787
-903,649
| -93% | -$2.68M | ﹤0.01% | 6061 |
|
|
2020
Q4 | $2.36M | Buy |
975,436
+691,534
| +244% | +$1.58M | ﹤0.01% | 3803 |
|
|
2020
Q3 | $650K | Buy |
283,902
+277,676
| +4,460% | +$729K | ﹤0.01% | 4520 |
|
|
2020
Q2 | $14K | Buy |
6,226
+901
| +17% | +$2.08K | ﹤0.01% | 6357 |
|
|
2020
Q1 | $9K | Hold |
5,325
| – | – | ﹤0.01% | 6403 |
|
|
2019
Q4 | $11K | Sell |
5,325
-247
| -4% | -$586 | ﹤0.01% | 6636 |
|
|
2019
Q3 | $16K | Buy |
5,572
+3,072
| +123% | +$10.5K | ﹤0.01% | 6637 |
|
|
2019
Q2 | $10K | Hold |
2,500
| – | – | ﹤0.01% | 6740 |
|
|
2019
Q1 | $12K | Hold |
2,500
| – | – | ﹤0.01% | 6618 |
|
|
2018
Q4 | $6K | Hold |
2,500
| – | – | ﹤0.01% | 6746 |
|
|
2018
Q3 | $16K | Sell |
2,500
-7,726
| -76% | -$40.8K | ﹤0.01% | 6564 |
|
|
2018
Q2 | $70K | Buy |
10,226
+6,746
| +194% | +$50.5K | ﹤0.01% | 5978 |
|
|
2018
Q1 | $29K | Buy |
3,480
+2,924
| +526% | +$24.3K | ﹤0.01% | 6262 |
|
|
2017
Q4 | $6K | Buy |
556
+281
| +102% | +$2.83K | ﹤0.01% | 6718 |
|
|
2017
Q3 | $3K | Sell |
275
-519
| -65% | -$19.7K | ﹤0.01% | 6831 |
|
|
2017
Q2 | $33K | Buy |
794
+533
| +204% | +$25.7K | ﹤0.01% | 6047 |
|
|
2017
Q1 | $13K | Buy |
261
+202
| +342% | +$7.89K | ﹤0.01% | 6477 |
|
|
2016
Q4 | $2K | Hold |
59
| – | – | ﹤0.01% | 6869 |
|
|
2016
Q3 | $2K | Sell |
59
-924
| -94% | -$36.3K | ﹤0.01% | 6871 |
|
|
2016
Q2 | $32K | Buy |
983
+733
| +293% | +$26.9K | ﹤0.01% | 6042 |
|
|
2016
Q1 | $15K | Sell |
250
-78
| -24% | -$2.48K | ﹤0.01% | 6259 |
|
|
2015
Q4 | $14K | Buy |
328
+313
| +2,087% | +$14.9K | ﹤0.01% | 6576 |
|
|
2015
Q3 | $1K | Sell |
15
-69
| -82% | -$6.84K | ﹤0.01% | 7092 |
|
|
2015
Q2 | $9K | Buy |
+84
| New | +$7.8K | ﹤0.01% | 6635 |
|
|
2015
Q1 | – | Sell |
-25
| Closed | -$1K | – | 7799 |
|
|
2014
Q4 | $1K | Sell |
25
-88
| -78% | -$6.01K | ﹤0.01% | 7585 |
|
|
2014
Q3 | $8K | Sell |
113
-48
| -30% | -$5.26K | ﹤0.01% | 7424 |
|
|
2014
Q2 | $24K | Buy |
161
+48
| +42% | +$7.28K | ﹤0.01% | 7096 |
|
|
2014
Q1 | $16K | Buy |
+113
| New | +$13.8K | ﹤0.01% | 7021 |
|
Other funds holding GNCA
Bank of America's GNCA Position: Q2 2022 in Review
Bank of America sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 57,363 shares — an estimated $72K sold.
Bank of America first reported a position in GNCA in Q1 2014 and held it in 32 quarters. The position peaked at $2.36M in Q4 2020. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- Bank of America reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- Bank of America sold 57,363 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $72K.
- Bank of America first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 32 quarters.
- Bank of America's Genocea Biosciences, Inc. position peaked at $2.36M in Q4 2020.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on Bank of America's 13F filing for Q2 2022, filed 12 Aug 2022.